High serum phosphate may protect against hyperuricaemia in hypertensive patients
There appears to be an inverse association between serum phosphate levels and the risk of developing hyperuricaemia among adult patients with hypertension, a study has found.
Researchers performed a posthoc analysis of the Uric Acid substudy of the China Stroke Primary Prevention Trial, including 10,612 participants with normal uric acid levels (<357 μmol/L [6 mg/dL]) at baseline.
In the cohort, the mean serum phosphate level was 1.3 mmol/L. Prevalence rates of mild (<0.8 mmol/L), moderate (<0.6 mmol/L) and severe (<0.4 mmol/L) hypophosphatemia were 1.0 percent, 0.4 percent and 0.4 percent, respectively. None of the participants with hypophosphatemia had arrhythmia or cardiomyopathy.
The primary outcome of new-onset hyperuricaemia, defined as a uric acid concentration of ≥417 μmol/L (7 mg/dL) in men or ≥357 μmol/L (6 mg/dL) in women, occurred in 1,663 participants (15.7 percent) over a median follow-up of 4.4 years.
Serum phosphate had a significant inverse association with the risk of new-onset hyperuricaemia (odds ratio [OR] per SD increment, 0.71; 95 percent CI, 0.66–0.76). When serum phosphate was assessed as quartiles, the risk was lowest in participants in quartile 4 (≥1.4 mmol/L; OR, 0.48; 0.40–0.57) relative to those in quartile 1 (<1.2 mmol/L). Results were similar in males and females.
The present data suggest that serum phosphate measurements, along with other known risk factors, may help pinpoint which hypertensive patients are at high risk of new-onset hyperuricaemia, researchers said. Targeting this high-risk population and implementing early management of multiple risk factors should reduce the risk of future hyperuricaemia and related diseases.